Mair Therapeutics, a Nijmegen, the Netherlands-based biotechnology startup developing treatments for neurodegenerative disorders, raised an undisclosed amount in Pre-Seed funding.
The round was led by Torrey Pines Investment.
The company intends to use the funds to expand operations an its developement efforts.
Mair Therapeutics is dedicated to discovering compounds that regulate the lysosomal ion channel TMEM175, which controls lysosomal pH to maintain optimal conditions for degrading protein aggregates – hallmarks of Parkinson’s disease.
FinSMEs
14/02/2025